Literature DB >> 26681760

Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study.

Gudbjörg Jonsdottir1, Sigrún H Lund1, Magnus Björkholm2, Ingemar Turesson3, Anders Wahlin4, Sham Mailankody5, Cecilie Blimark6, Malin Hultcrantz2, Anna Porwit7, Ola Landgren8, Sigurdur Y Kristinsson9.   

Abstract

Entities:  

Keywords:  multiple myeloma; population-based; second malignancy; survival

Mesh：

Substances：

Year:  2015        PMID： 26681760      PMCID： PMC5004397          DOI： 10.3324/haematol.2015.134049

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Improved long-term survival in multiple myeloma up to the age of 80 years.

Authors:  S Y Kristinsson; W F Anderson; O Landgren
Journal:  Leukemia       Date:  2014-01-14       Impact factor: 11.528

2.  Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.

Authors:  Chenjie Zeng; Wanqing Wen; Alicia K Morgans; William Pao; Xiao-Ou Shu; Wei Zheng
Journal:  JAMA Oncol       Date:  2015-04       Impact factor: 31.777

3.  Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS).

Authors:  Sham Mailankody; Ruth M Pfeiffer; Sigurdur Y Kristinsson; Neha Korde; Magnus Bjorkholm; Lynn R Goldin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2011-07-27       Impact factor: 22.113

4.  Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.

Authors:  Monika Engelhardt; Gabriele Ihorst; Ola Landgren; Milena Pantic; Heike Reinhardt; Johannes Waldschmidt; Annette M May; Martin Schumacher; Martina Kleber; Ralph Wäsch
Journal:  Haematologica       Date:  2015-07-09       Impact factor: 9.941

5.  Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.

Authors:  Antonio Palumbo; Sara Bringhen; Shaji K Kumar; Giulia Lupparelli; Saad Usmani; Anders Waage; Alessandra Larocca; Bronno van der Holt; Pellegrino Musto; Massimo Offidani; Maria T Petrucci; Andrea Evangelista; Sonja Zweegman; Ajay K Nooka; Andrew Spencer; Meletios A Dimopoulos; Roman Hajek; Michele Cavo; Paul Richardson; Sagar Lonial; Giovannino Ciccone; Mario Boccadoro; Kenneth Anderson; Bart Barlogie; Pieter Sonneveld; Philip L McCarthy
Journal:  Lancet Oncol       Date:  2014-02-11       Impact factor: 41.316

6.  Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.

Authors:  Gautam Borthakur; E Lin; Nitin Jain; Elihu E Estey; Jorge E Cortes; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Sherry Pierce; Hagop Kantarjian
Journal:  Cancer       Date:  2009-07-15       Impact factor: 6.860

7.  Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.

Authors:  Naveen Pemmaraju; Dhaval Shah; Hagop Kantarjian; Robert Z Orlowski; Graciela M Nogueras González; Veera Baladandayuthapani; Nitin Jain; Verena Wagner; Guillermo Garcia-Manero; Jatin Shah; Farhad Ravandi; Sherry Pierce; Koichi Takahashi; Naval Daver; Aziz Nazha; Srdan Verstovsek; Elias Jabbour; Marcos De Lima; Richard Champlin; Jorge Cortes; Muzaffar H Qazilbash
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-07-15

8.  Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.

Authors:  C Schoch; W Kern; S Schnittger; W Hiddemann; T Haferlach
Journal:  Leukemia       Date:  2004-01       Impact factor: 11.528

9.  Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study.

Authors:  Ingemar Turesson; Ramon Velez; Sigurdur Y Kristinsson; Ola Landgren
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544

10.  Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score.

Authors:  M Kleber; G Ihorst; M Terhorst; B Koch; B Deschler; R Wäsch; M Engelhardt
Journal:  Blood Cancer J       Date:  2011-09-16       Impact factor: 11.037
View more
  5 in total

Review 1.  Treatment and disease-related complications in multiple myeloma: Implications for survivorship.

Authors:  Rajshekhar Chakraborty; Navneet S Majhail
Journal:  Am J Hematol       Date:  2020-03-13       Impact factor: 10.047

Review 2.  B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.

Authors:  Ryan B Sinit; Dick G Hwang; Prakash Vishnu; Jess F Peterson; David M Aboulafia
Journal:  BMC Cancer       Date:  2019-11-27       Impact factor: 4.430

3.  Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018.

Authors:  Jing Wang; Chenglan Lv; Min Zhou; Jing-Yan Xu; Bing Chen; Yuan Wan
Journal:  Cancers (Basel)       Date:  2022-10-07       Impact factor: 6.575

Review 4.  Second primary malignancies in multiple myeloma: A review.

Authors:  Christina Poh; Theresa Keegan; Aaron Seth Rosenberg
Journal:  Blood Rev       Date:  2020-09-06       Impact factor: 8.250

5.  Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan.

Authors:  Yanfang Liu; Hsin-An Hou; Hong Qiu; Chao-Hsiun Tang
Journal:  Sci Rep       Date:  2020-09-01       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.